Extra Corporeal Membrane Oxygenation (ECMO) System Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Extra Corporeal Membrane Oxygenation (ECMO) System Market is segmented by Modality (Veno-Arterial (VA), Veno-Venous (VV) and Others), By Application (Respiratory Applications, Cardiac Applications, Extracorporeal Cardiopulmonary Resuscitation (ECPR)) and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

ECMO System Market
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.71 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Extra Corporeal Membrane Oxygenation (ECMO) System Market is projected to register a CAGR of 4.71% during the forecast period (2022-2027).

Extracorporeal membrane oxygenation is a life-supporting device that helps patients with severe respiratory failure by providing respiratory and cardiac support. The pandemic positively impacted the expansion of the extracorporeal membrane oxygenation market. An article published in September 2021 by the Regents of the University of Michigan states that new findings are published in Lancet by an international team co-led by ECMO experts from the University of Michigan, Singapore, and Columbia University. The paper uses data from over 4,800 patients over age 16 treated with ECMO for advanced COVID-19 in 41 countries during 2020. Furthermore, ECMO machines were used to treat critical COVID-19 patients during the epidemic, raising global awareness of the device. As a result, rising patient knowledge and education of ECMO will favor market dynamics. During the first half of 2021, a sudden spike in COVID-19 cases worldwide necessitated the continuous use of enhanced life support.

A review published by Froedtert & the Medical College of Wisconsin in October 2021 states that the lungs get stiffer in COVID conditions, and the pressure to push blood through the lungs goes up, which is termed pulmonary hypertension. This condition strains the heart's right side and causes it to fail. When the body fails to this degree, that is when ECMO plays a vital role and helps the patients to revive their conditions. As a result of the impaired respiratory health caused by a lung infection and long-term symptoms, the danger of respiratory failure increases, necessitating the use of ECMO equipment during the pandemic. Additionally, for COVID-19 patients, veno-venous extracorporeal membrane oxygenation (VV ECMO) has been employed as a life-saving therapy. As a result of the continuous rise in COVID-19 patients, global demand for ECMO devices has increased. The pandemic became the most significant cause of mortality for people aged 45 to 84 in 2020. The ECMO system takes over the lungs and/or heart functions, allowing critically ill adults to recover more quickly. As a result, the regional market data will be boosted by an increase in the number of critically sick patients combined with an increase in the use of an ECMO machines.

Excessive smoking, tobacco intake, and alcohol consumption contribute to the existing burden of lung diseases, increasing global market demand. World Health Organization (WHO) data updated on May 2022 states that 3 million deaths every year result from harmful use of alcohol, and it represents 5.3% of all deaths. Alcohol consumption causes death and disability relatively early in life. In people aged 20–39 years, approximately 13.5% of total deaths are attributable to alcohol. Thus, the higher consumption leads to severe cardiovascular diseases, and increasing cardiovascular diseases promotes the adoption rate of ECMO therapy and is predicted to increase as patients become more aware of the significance of cardiopulmonary assistance for severe cardiac and respiratory problems. World Health Organization (WHO) data updated on May 2022 states that cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. The introduction of patient education campaigns on the ECMO device and its use in emerging economies has increased demand. The need for veno-venous ECMO is predicted to rise in the coming years as the prevalence of cardiopulmonary disorders rises. In addition, ongoing advancements in the veno-venous method will help segmental expansion by offering effective therapy. The benefits of these devices, such as lower recirculation rates, simplicity of mobility, and lower risk of bleeding, are expected to boost total market statistics. In 2021, more than 33,000 children patients got ECMO support worldwide, according to the Extracorporeal Life Support Organization (ELSO) registry. World Health Organization (WHO) data updated on May 2021 states that cardiovascular diseases account for most Non-communicable diseases (NCDs) deaths, or 17.9 million people annually, followed by cancers, respiratory diseases, and diabetes. The industry also benefits from the rising survival rate of ECMO machine-assisted surgery for cardiac and respiratory patients. The use of ECMO machines has grown in popularity throughout the years. ECMO machines were once only employed in circulatory or respiratory failure, and their uses have expanded to include post-organ transplantation, sepsis, and heart failure. All these factors accelerate the growth in the market.

However, the market growth is expected to slow down due to the increasing cost of ECMO procedures. The risks associated with the ECMO system also contribute to the decline of market growth.

Scope of the Report

As per the scope of this report, Extracorporeal membrane oxygenation (ECMO), also known as extracorporeal life support (ECLS), is an extracorporeal technique of providing prolonged cardiac and respiratory support to persons whose heart and lungs are unable to provide an adequate amount of gas exchange or perfusion to sustain life. The technology for ECMO is primarily derived from cardiopulmonary bypass, which provides shorter-term support with arrested native circulation. The Extra Corporeal Membrane Oxygenation (ECMO) System Market is segmented by Modality (Veno-Arterial (VA), Veno-Venous (VV), and Others), By Application (Respiratory Applications, Cardiac Applications, Extracorporeal Cardiopulmonary Resuscitation (ECPR)) and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD million) for the above segments.

By Modality
Veno-Arterial (VA)
Veno-Venous (VV)
By Application
Respiratory Applications
Cardiac Applications
Extracorporeal Cardiopulmonary Resuscitation (ECPR)
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Respiratory Applications is expected to Dominate the Market

Meconium aspiration syndrome, pneumonia, congenital diaphragmatic hernia (CDH), and respiratory distress syndrome are among the disorders that the ECMO device is used to treat in infants. The extracorporeal membrane oxygenation market is divided into three categories based on the patient population: infant, pediatric, and adult. A significant factor in the segment's growth is the danger of respiratory failure among individuals with various respiratory illnesses. Furthermore, increased tobacco use and smoking have a negative impact on lung health and can result in respiratory failure or chronic diseases. According to the Office of Disease Prevention and Health Promotion, data published in June 2020, asthma and chronic obstructive pulmonary disease (COPD) are significant public health burdens. Specific detection, intervention, and treatment methods may reduce this burden and promote health. According to the Office of Disease Prevention and Health Promotion data published in June 2020, more than 25 million people in the United States have asthma. Approximately 14.8 million adults have been diagnosed with COPD, and about 12 million people have not yet been diagnosed. In addition, the growing geriatric population is expected to increase respiratory diseases. The growing senior population, which is more susceptible to respiratory ailments, is expected to drive rising demand for respiratory treatment. As a result, rising disease burdens will drive product adoption rates in the coming years.

ECMO patients' survival rates differ based on the underlying disease and the patient's age. Patients with potentially reversible respiratory failure, such as severe acute respiratory distress syndrome (ADRs), primary graft dysfunction after a lung transplant, and pulmonary trauma, are considering Veno-Venous (VV) ECMO. Patients with respiratory failure who receive VV-ECMO have a higher chance of surviving. The rising prevalence of target diseases, the growing need for early detection and diagnostic imaging, and technological improvements in the ECMO machine market contribute to market growth.

ECMO is widely used in newborns with respiratory distress due to its several benefits, such as it is highly associated with low survival rates. On the other hand, recent technological developments in ECMO circuits have decreased the number of technical faults and complications. Extracorporeal membrane oxygenation (ECMO) is becoming more widely used, accelerating technological improvement in these devices. Hollow pumps, oxygenators, and heparin-coated cannulas have all been developed and are now employed in various surgical procedures. All these factors accelerate the segmental growth in the market.


North America is Expected to Dominate the Market

North America dominated the global market and accounted for the largest revenue share, owing to its increasing prevalence of cardiovascular and respiratory diseases, technological advancements in ECMO technology, and increased adoption of ECMO systems. For instance, according to the data published by the Centers for Disease Control and Prevention (CDC), in February 2022, 659,000 people in the United States die from heart disease each year which is 1 in every four deaths. Addition to, about 805,000 people in the United States have heart attacks. The need for Extracorporeal Membrane Oxygenation (ECMO) in the region is also increasing because of the increased adoption of advanced technical items and changes in lifestyle choices that result in chronic diseases such as cardiac and respiratory ailments. An increase in the number of advancements and advanced technology in these Extracorporeal Membrane Oxygenation (ECMO) devices, as well as a growth in public knowledge about their wide-ranging applications, has resulted in a large amount of output for hospitals.

Moreover, in the United States, high blood pressure, obesity, type-2 diabetes, and poor dietary habits have all increased cardiovascular disease cases. The use of ECMO (extracorporeal membrane oxygenation) has the potential to minimize the frequency of in-hospital deaths. Furthermore, according to the American Thoracic Society (ATS), data published in March 2022 estimates that the United States spends about USD 80 billion on asthma-related costs yearly. Given the high death rates from cardiovascular diseases and the increased expenditure on asthma treatment, the industry under consideration has a lot of room for expansion

Additionally, the market for Extracorporeal Membrane Oxygenation (ECMO) is growing due to increased healthcare spending by government organizations to improve healthcare services. Furthermore. The market is likely to be driven by reimbursement policies such as Medicare and Medicaid, which reimburse patients undergoing the Extracorporeal Membrane Oxygenation (ECMO) process. . All these factors are projected to have an impact on the market growth in the region.

image 2

Competitive Landscape

The Extra Corporeal Membrane Oxygenation (ECMO) System Market is competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some companies currently dominating the market are LivaNova (Alung Technologies Inc.), Eurosets, Getinge AB, Livanova Plc, Medtronic PLC, Microport Scientific Corporation, Nipro Medical Corporation, Terumo Medical Corporation, Abbott Laboratories, and Fresenius Medical Care Company (Xenios AG)​​​​.

Recent Development

In May 2022, MicroPort Scientific Corporation acquired Hemovent GmbH and Hemovent GmbH's MOBYBOX ECMO System for the Treatment of COVID-19 Patients Published in Leading International Medical Journal-ASAIO Journal.

In May 2022, ALung Technologies, Inc. was acquired by LivaNova PLC. The acquisition was made after the company received Food and Drug Administration (FDA) approval to market its artificial lung system, the Hemolung Respiratory Assist System.

Table of Contents


    1. 1.1 Study Assumptions & Market Defination

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Cardiovascular and Respiratory Diseases

      2. 4.2.2 Technological Advancements in ECMO Technology

      3. 4.2.3 Increased Adoption of ECMO Systems

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of ECMO Procedures

      2. 4.3.2 Risks Associated with ECMO System

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Modality

      1. 5.1.1 Veno-Arterial (VA)

      2. 5.1.2 Veno-Venous (VV)

      3. 5.1.3 Others

    2. 5.2 By Application

      1. 5.2.1 Respiratory Applications

      2. 5.2.2 Cardiac Applications

      3. 5.2.3 Extracorporeal Cardiopulmonary Resuscitation (ECPR)

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 LivaNova (Alung Technologies Inc.)

      2. 6.1.2 Eurosets

      3. 6.1.3 Getinge AB

      4. 6.1.4 Medtronic PLC

      5. 6.1.5 Microport Scientific Corporation

      6. 6.1.6 Nipro Medical Corporation

      7. 6.1.7 Terumo Medical Corporation

      8. 6.1.8 Abbott Laboratories

      9. 6.1.9 Fresenius Medical Care Company (Xenios AG)

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Extra Corporeal Membrane Oxygenation (ECMO) System Market market is studied from 2019 - 2027.

The Global Extra Corporeal Membrane Oxygenation (ECMO) System Market is growing at a CAGR of 4.71% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

LivaNova (Alung Technologies Inc.), Eurosets, Getinge AB, Medtronic PLC , Terumo Medical Corporation are the major companies operating in Global Extra Corporeal Membrane Oxygenation (ECMO) System Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!